Cancer cells deficient in cGAS or STING were resistant to this combination therapy, suggesting that CHK1 inhibitors enhance antitumor immunity by activating the cancer cell’s intrinsic cGAS-STING pathway. The gene discussed is CGAS; the disease is cancer.